StockTipsArenaBeta

BUY Strides Pharma Science Limited — Nilesh Jain, Centrum Broking

BUYStrides Pharma Science Limited

byNilesh Jain, Centrum BrokingHorizon: 1–3 months7 Sept 2026via NDTV Profit

Entry₹1,156Inferred
Target₹1,200
Total upside +3.81%
Stop loss₹1,100-4.84% risk
CMP₹1,178.814h ago
Active+1.97%+1.80%upside left 3 mo left
Follow Nilesh Jain for new calls(36% target hit, 33 closed calls)Get alertsWatch STAR for new buy/sell callsGet alertsSee 15 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 7:03 am IST
6 supporting2 neutral1 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·8 Sept · today

Past month's volume 2.1× the prior month's average

Technicals · volume·7 Sept · yesterday

Strides Pharma Science Ltd has received an Establishment Inspection Report (EIR) from the USFDA for its Bengaluru facility. This is a positive development for the company's regulatory compliance and o

BSE · Company Update·19 Aug · 3w ago

(opens in new tab)

HSBC chooses this AC company to upgrade after Q1 results despite peer outperforming

NewsCnbc-Tv18·18 Aug · 3w ago

(opens in new tab)

Voltas could see over 35% profit growth as AC demand stays strong, margins recover: Equirus

NewsCnbc-Tv18·17 Aug · 3w ago

(opens in new tab)
Neutral / worth noting (2)

Buy, Sell Or Hold: Tata Motors, Vodafone Idea, Varun Beverages, Star Health And Power Finance — Ask Profit

NewsNdtv-Profit·26 Aug · 2w ago

(opens in new tab)

Blue Star among 4 F&O stocks with a sharp rise in futures open interest

NewsEt-Markets·20 Aug · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 93 — overbought territory

Technicals · rsi·8 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.